Krka Finds Romanian Allegations Unjustified
But Will Aim To ‘Improve Transparency And Compliance’
Executive Summary
Krka has denied giving its Romanian unit instructions to bribe healthcare professionals, following an internal investigation spurred by media reports of “irregularities” at the subsidiary.
You may also be interested in...
Krka Responds To Romanian Allegations
Slovenia’s Krka has responded to media reports of “irregularities” at its Romanian subsidiary – including allegations of bribing local doctors to prescribe its products – by pledging to form a special investigation team to immediately examine the matter.
Apotex And Ambio Shatter Hopes Of Teriparatide Exclusivity For Teva
Partners Apotex and Ambio have announced approval of a second US teriparatide generic from the FDA, adding another Forteo rival to the market and removing hopes that Teva’s recently approved first generic could benefit from 180 days of market exclusivity. Further competition is also in the works with Amphastar awaiting FDA action on a further teriparatide ANDA.
Fresenius And Formycon File Ustekinumab In US
Partners Fresenius Kabi and Formycon have submitted a US filing for their FYB202 ustekinumab biosimilar rival to Stelara.